Harvard Bioscience, Inc. (HBIO)
After hours:
| Previous close | 3.8200 |
| Open | 3.8900 |
| Bid | 3.8000 x 100 |
| Ask | 3.9600 x 100 |
| Day's range | 3.7802 - 3.9500 |
| 52-week range | 3.4400 - 6.2500 |
| Volume | |
| Avg. volume | 93,391 |
| Market cap | 167.172M |
| Beta (5Y monthly) | 1.45 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET
HOLLISTON, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2024 before the market opens on May 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-onl
- GlobeNewswire
Harvard Bioscience Announces Action to Improve Operational Efficiency and Support Ongoing Investments in Growth
HOLLISTON, Mass., April 09, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced a labor force reduction to improve its operating cost structure and support its ongoing investments in growth. The Company expects to realize overall annual run rate savings of approximately $4 million beginning in the second quarter of 2024. The Company also expects second quarter restructuring-related charges of approximately $0.5 million. Jim Green, Harvard Bioscience Chairman and CEO,
- GlobeNewswire
Harvard Bioscience, Inc. to Participate in March 2024 Investor Conferences: Sidoti’s Small Cap Conference and KeyBanc’s Life Sciences & MedTech Conference
HOLLISTON, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, will be presenting to investors at the upcoming Sidoti Small Cap Conference and KeyBanc Life Sciences & MedTech Conference, both to be held virtually in March 2024. Joining him will be Jennifer Cote, the Company’s Chief Financial Officer. Both presentations will be webcast live and can be accessed through the investor relations section
